VOLITIONRX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8 USD | +1.66% |
|
-1.22% | +11.58% |
| May. 14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
| May. 13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 4.46M | Sales 2025 * | 16.2M | Capitalization | 65.69M |
|---|---|---|---|---|---|
| Net income 2024 * | -35M | Net income 2025 * | -31M | EV / Sales 2024 * | 12.2 x |
| Net cash position 2024 * | 11.2M | Net Debt 2025 * | 13.9M | EV / Sales 2025 * | 4.91 x |
| P/E ratio 2024 * |
-1.78
x | P/E ratio 2025 * |
-2.5
x | Employees | 110 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on VolitionRx Limited
More recommendations
| 1 day | +1.66% | ||
| 1 week | -1.22% | ||
| Current month | -11.10% | ||
| 1 month | +29.03% | ||
| 3 months | -23.08% | ||
| 6 months | +5.26% | ||
| Current year | +11.58% |
1 week
0.74
0.90
1 month
0.571.02
Current year
0.571.23
1 year
0.551.79
3 years
0.554.14
5 years
0.556.84
10 years
0.559.28
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Terig Hughes
DFI | Director of Finance/CFO | 54 | 21-01-31 |
Gaetan Michel
COO | Chief Operating Officer | 51 | 21-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Martin Faulkes
CHM | Chairman | 80 | 11-10-05 |
Guy Innes
BRD | Director/Board Member | 67 | 11-10-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 0.8 | +1.66% | 50,923 |
| 24-05-15 | 0.7869 | +4.92% | 99,280 |
| 24-05-14 | 0.75 | -14.53% | 312,875 |
| 24-05-13 | 0.8775 | +5.85% | 309,762 |
| 24-05-10 | 0.829 | +2.36% | 83,603 |
Delayed Quote Nyse, May 16, 2024 at 04:00 pm EDT
More quotes
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8
USD
Average target price
3.725
USD
Spread / Average Target
+365.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.58% | 64.61M | |
| -29.78% | 9.84B | |
| -2.96% | 3.15B | |
| +28.23% | 2.99B | |
| -14.73% | 2.15B | |
| -15.05% | 1.8B | |
| +69.62% | 1.49B | |
| +23.08% | 770M | |
| -2.84% | 762M | |
| -24.08% | 575M |
- Stock Market
- Equities
- VNRX Stock
